DURECT (NASDAQ:DRRX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $6.91 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
DURECT Price Performance
Shares of DRRX stock opened at $0.85 on Tuesday. The stock’s 50-day moving average is $0.80 and its 200 day moving average is $1.02. DURECT has a 1-year low of $0.70 and a 1-year high of $1.88. The company has a market cap of $26.35 million, a P/E ratio of -1.39 and a beta of 0.91.
Analyst Upgrades and Downgrades
Separately, StockNews.com assumed coverage on shares of DURECT in a report on Wednesday, March 19th. They issued a “sell” rating on the stock.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Read More
- Five stocks we like better than DURECT
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- What is diluted earnings per share (Diluted EPS)?
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Stock Splits, Do They Really Impact Investors?
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
